البلد: نيوزيلاندا
اللغة: الإنجليزية
المصدر: Medsafe (Medicines Safety Authority)
Sulfamethoxazole 40 mg/mL; Trimethoprim 8 mg/mL
AFT Pharmaceuticals Ltd
Sulfamethoxazole 40 mg/mL
40mg/200mg per 5mL
Oral suspension
Active: Sulfamethoxazole 40 mg/mL Trimethoprim 8 mg/mL Excipient: Carmellose sodium Citric acid Dispersible cellulose Glycerol Sodium citrate Polysorbate 80 Ponceau 4R Purified water Raspberry flavour E_0026934 Sodium methyl hydroxybenzoate Sodium propyl hydroxybenzoate Syrup
Bottle, glass, Amber Type III with PP child resistant cap 100 mL., 100 mL
Prescription
Prescription
Virchow Laboratories Limited
Package - Contents - Shelf Life: Bottle, glass, Amber Type III with PP child resistant cap 100 mL. - 100 mL - 36 months from date of manufacture stored at or below 25°C
2008-12-04
NEW ZEALAND DATA SHEET 1. DEPRIM Deprim oral suspension, sulfamethoxazole 200mg and trimethoprim 40mg per 5mL. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Deprim contains 200 mg Sulfamethoxazole and 40 mg trimethoprim per 5 mL. Excipients with known effect: For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral suspension. Deprim Suspension is a pink, raspberry flavoured suspension containing 200 mg Sulfamethoxazole and 40 mg trimethoprim per 5 mL. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Deprim has a broad spectrum of antibacterial activity and may be indicated for the following: Gastrointestinal tract infections: Treatment of cholera as an adjunct to fluid and electrolyte replacement when the organism has been shown to be sensitive in vitro Treatment of Shigellosis (may be less effective in some parts of the world due to resistant organisms) Treatment of travellers’ diarrhoea including gastroenteritis due to enterotoxigenic E. coli Genital tract infections: Treatment of gonorrhoea including oro-pharyngeal and ano-rectal infection Treatment of chancroid (may be less effective in some parts of the world due to resistant organisms Treatment of ganuloma inguinale (venereum) Urinary tract infections: Treatment of acute uncomplicated urinary tract infections. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a singleeffective antibacterial agent rather than the combination. Respiratory tract infections: Treatment of otitis media. Deprim is not indicated for prophylactic or prolonged administration in otitis media Treatment of acute exacerbations of chronic bronchitis Treatment and prevention of Pneumocystis jirovecii Other: Treatment and prophylaxis of toxoplasmosis Treatment of nocardosis There are a number of other bacterial conditions caused by sensitive organisms for which treatment with Deprim may be appropriate. The use of Deprim should be based on clinical experience and local in اقرأ الوثيقة كاملة